



ASX ANNOUNCEMENT

9 July 2021

Update on recovery of missing funds

9 July 2021 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) announced today that it has received \$1.2 million in connection with court proceedings seeking to recover funds that were the subject of the cyber security incident announced to the market on 8 February 2021. As further announced on 29 March 2021, the Company had commenced a civil proceeding in Hong Kong to seek recovery of funds.

Criminal investigations are continuing in various jurisdictions, however there is no guarantee that any formal prosecutions against any third parties involved in the cyber incident will either commence or result in any further funds being recovered.

Authorised for release by Geraldine Farrell, Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088
clive.fanning@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouplimited.com | www.satipharm.com